Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10932)
  2. Meeting Abstract (9499)
  3. Review (556)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22242)
  2. GSK Faculty (5929)
  3. Genitourinary Oncology Service (5651)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4155)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (642)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1043)
  6. Springer (981)

More Publishers

Results (22265)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biomarker analysis and updated clinical outcomes: Neoadjuvant systemic treatment (NST) with nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma
    Meeting Abstract

    Burton, E. M.; Wani, K. M.; Milton, D. R.; Segura, R. L.; Tetzlaff, M.; Ross, M. I.; Postow, M. A.; Glitza, I. C.; Wong, M. K. K.; Diab, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results
    Meeting Abstract

    Funt, S. A.; Grivas, P.; Gao, X.; Vaena, D. A.; Zhang, T.; Milowsky, M. I.; Rao, M.; Liu, H.; Tipton, K.; An, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2-breast cancer (BC) cohorts of EV-202
    Meeting Abstract

    Giordano, A.; Awan, A. A. A.; Bruce, J. Y.; Rugo, H. S.; Diamond, J. R.; Novik, Y.; Baranda, J. C.; Muro, K.; Ono, M.; Nanda, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
    Meeting Abstract

    Mitchell, S.; Khan, B.; Payumo, F.; Chiorean, E. G.; Gahvari, Z.; Hecht, J. R.; Hurwitz, M. E.; Leidner, R.; Lenz, H. J.; Pelster, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade
    Meeting Abstract

    Ricciuti, B.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Citarella, F.; Gandhi, M. M.; Elkrief, A.; Pecci, F.; Alessi, J. V. M.; Di Federico, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial
    Meeting Abstract

    Matar, S.; Jegede, O.; Denize, T.; Ghandour, F.; Laimon, Y. N.; El Ahmar, N.; Sheshdeh, A. B.; Savla, V.; Mohanna, R. A.; Catalano, P. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001
    Meeting Abstract

    Pal, S. K.; Medioni, J.; de Velasco, G.; Merchan, J. R.; Büchler, T.; Apolo, A. B.; Loriot, Y.; Wang, Z.; Jew, T.; Cao, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Wagner, A. J.; Trent, J. C.; Attia, S.; Agulnik, M.; Wilky, B. A.; Tap, W. D.; von Mehren, M.; Davis, E. J.; Zou, L.; Shah, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2-p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study
    Meeting Abstract

    Peltzer, A.; LoRusso, P.; Gounder, M. M.; Yamamoto, N.; Somaiah, N.; Lugowska, I. A.; Moreno, V.; Teufel, M.; Jayadeva, G.; Hesse, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study
    Meeting Abstract

    Chandana, S. R.; Shepard, D. R.; Mehnert, J. M.; Chi, P.; Trent, J. C.; Psoinos, C. M.; Zhou, B.; Black, V.; Viswanathan, L.; Gozo, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save